Get the Stockscreener App
4.365
5.11%
-0.235
Pre-market:
4.32
-0.045
-1.03%
Pyxis Oncology Inc stock is traded at $4.365, with a volume of 701.89K.
It is down -5.11% in the last 24 hours and up +11.92% over the past month.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
See More
Previous Close:
$4.60
Open:
$4.52
24h Volume:
701.89K
Relative Volume:
0.82
Market Cap:
$271.78M
Revenue:
-
Net Income/Loss:
$-73.79M
P/E Ratio:
-2.3723
EPS:
-1.84
Net Cash Flow:
$-77.44M
1W Performance:
-17.33%
1M Performance:
+11.92%
6M Performance:
+241.02%
1Y Performance:
+142.50%
1-Day Range:
$4.25
$4.59
1-Week Range:
$3.67
$5.42
52-Week Range:
$0.8332
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Name
Pyxis Oncology Inc
Sector
Industry
Phone
(617) 221-9059
Address
321 HARRISON AVENUE, BOSTON
Compare PYXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
4.365 | 286.42M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Nov-21-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-08-24 | Initiated | Stephens | Overweight |
| Aug-08-24 | Initiated | Stifel | Buy |
| May-07-24 | Resumed | Jefferies | Buy |
| Feb-09-24 | Initiated | BTIG Research | Buy |
| Jan-23-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-02-21 | Initiated | BofA Securities | Neutral |
| Nov-02-21 | Initiated | Credit Suisse | Outperform |
| Nov-02-21 | Initiated | Jefferies | Buy |
View All
Pyxis Oncology Inc Stock (PYXS) Latest News
Will Pyxis Oncology Inc. stock reach Wall Street targetsPortfolio Value Report & Risk Controlled Daily Trade Plans - Newser
Its Stock Has Paid Off Big Time For Pyxis Oncology Inc - Setenews
Pyxis Oncology Keeps Losses Steady As It Eyes Key Trial Data - Finimize
Leerink Partnrs Lowers Earnings Estimates for Pyxis Oncology - Defense World
Pyxis Oncology Files $350 Million Mixed Shelf - marketscreener.com
Pyxis Oncology: MICVO Data Could Be The Tipping Point In 2025 - RTTNews
What drives Pyxis Oncology Inc stock priceStock Screening Results & Free Real-Time Trading Signals - earlytimes.in
Stephens Reaffirms Their Buy Rating on Pyxis Oncology (PYXS) - The Globe and Mail
Stephens & Co. Maintains Pyxis Oncology (PYXS) Overweight Recommendation - Nasdaq
Stephens raises Pyxis Oncology stock price target to $8 on MICVO potential - Investing.com Nigeria
Ready to Jump After Recent Trade: Pyxis Oncology Inc (PYXS) - Setenews
Can Pyxis Oncology Inc. stock weather global recessionSell Signal & Weekly Return Optimization Plans - newser.com
Is Pyxis Oncology Inc. stock vulnerable to regulatory risksPortfolio Value Report & Weekly Momentum Picks - newser.com
What makes Pyxis Oncology Inc. stock attractive to growth funds2025 Market Outlook & Growth Focused Investment Plans - newser.com
Signal strength of Pyxis Oncology Inc. stock in tech scanners - newser.com
Tick level data insight on Pyxis Oncology Inc. volatilityJuly 2025 Decliners & Capital Efficient Trade Techniques - newser.com
Is Pyxis Oncology Inc. stock a bargain at current levels2025 Volatility Report & Weekly Consistent Profit Watchlists - newser.com
Applying Elliott Wave Theory to Pyxis Oncology Inc.July 2025 Fed Impact & Expert Approved Momentum Trade Ideas - newser.com
Can trapped investors hope for a rebound in Pyxis Oncology Inc.2025 Retail Activity & Free Weekly Chart Analysis and Trade Guides - newser.com
Pyxis Oncology Reports Increased Losses Amid Development Focus - TipRanks
Pyxis Oncology Inc (PYXS) looking to reclaim success with recent performance - Setenews
How to manage a losing position in Pyxis Oncology Inc.July 2025 Spike Watch & Community Consensus Trade Signals - newser.com
Is Pyxis Oncology Inc. stock gaining market shareJobs Report & Verified Chart Pattern Signals - newser.com
Is Pyxis Oncology Inc. stock cheap at current valuationJuly 2025 Spike Watch & High Return Trade Opportunity Guides - newser.com
Pyxis Oncology (PYXS) Price Target Increased by 13.33% to 6.94 - Nasdaq
Ranking Pyxis Oncology Inc. among high performing stocks via toolsQuarterly Risk Review & Daily Oversold Bounce Ideas - newser.com
What Fibonacci levels say about Pyxis Oncology Inc. reboundMarket Growth Summary & Stock Portfolio Risk Control - newser.com
Backtesting results for Pyxis Oncology Inc. trading strategiesMarket Sentiment Review & Growth Focused Investment Plans - newser.com
Published on: 2025-11-16 11:45:49 - newser.com
Will Pyxis Oncology Inc. stock continue upward momentumDividend Hike & AI Forecast for Swing Trade Picks - newser.com
Can Pyxis Oncology Inc. stock beat analyst upgradesIPO Watch & Weekly Chart Analysis and Trade Guides - newser.com
Brokerages Set Pyxis Oncology, Inc. (NASDAQ:PYXS) PT at $7.25 - Defense World
Will Pyxis Oncology Inc. stock see insider buyingStop Loss & Weekly Watchlist for Hot Stocks - Fundação Cultural do Pará
Stifel Nicolaus Remains a Buy on Pyxis Oncology (PYXS) - The Globe and Mail
Will Pyxis Oncology Inc. stock deliver better than expected guidancePortfolio Risk Summary & Verified Entry Point Signals - newser.com
Pyxis Oncology Inc Stock (PYXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):